BioNTech stock at USD 99.11 on September 28, 2026
Published on 09/28/2026 at 19:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
BioNTech SE stock was last traded at USD 99.11 on Nasdaq at 17:23:14 UTC on September 28, 2026. The shares were up 0.59 percent from the prior session's USD 98.52.
Updated lung cancer data
In a September 14 release, BioNTech SE and OncoC4 reported updated data from stage 1 of the randomized PRESERVE-003 Phase 3 trial. The study evaluated investigational gotistobart, also known as BNT316 or ONC-392, in patients with squamous non-small cell lung cancer whose disease had progressed after prior immunotherapy and chemotherapy.
The company reported median overall survival of 18.5 months for patients treated with gotistobart, compared with 10.0 months for patients treated with docetaxel. The reported hazard ratio was 0.56, with a nominal p-value of 0.0295. The data cutoff was July 17, 2026, and the median follow-up was 25.4 months.
The release said 87 patients were randomized in the non-pivotal stage 1 portion: 45 received gotistobart and 42 received docetaxel. The pivotal stage 2 portion was ongoing at more than 160 sites globally, according to BioNTech.
Development status
BioNTech described gotistobart as an investigational CTLA-4-targeting immunotherapy being jointly developed with OncoC4. The candidate has not been approved for the reported indication.
